Deschloroketamine or 2-oxo-PCM, is classed as an arylcyclohexylamine tranquilize. Ayrlcyclohexylamine drugs are named for their structures which incorporate a cyclohexane ring bound to a fragrant ring alongside an amine gathering. deschloroketamine  contains a phenyl ring attached to a cyclohexane ring substituted with an oxo gathering (cyclohexanone). An amino methyl chain (- N-CH3) is bound to the nearby alpha carbon (R2) of the cyclohexanone ring.

Descholoroketamine is a chiral particle and is frequently delivered as a racemate. Des-is a prefix utilized as a part of science to signify the nonappearance of an utilitarian gathering (for this situation “chloro”) subsequently deschloroketamine is named for without a chlorine substitution on its phenyl ring, which is found in ketamine.

Because of the absence of research with respect to the substance, all dialog in regards to the pharmacology of it is simply in view of its structure and subjective impact likenesses to 3-MeO-PCP, PCP and MXE.

Average measurements: few miligrams. If you don’t mind be cautious and do your exploration.

Deschloroketamine Compound Information

Equivalent words: Deschloroketamine or 2-oxo-PCM

IUPAC Name: 2-Phenyl-2-(methylamino)cyclohexanone

Sub-atomic Recipe: C13H17NO

Sub-atomic Mass: 203.29 g/mo

This item is expected for criminological and explore applications. Not for Human utilization
Deschloroketamine (DXE, DCK, 2′- Oxo-PCM) is a dissociative soporific that has been sold online as a creator medicate. It has likewise been proposed for the treatment of bacterial, contagious, viral or protozoal contaminations and for immunomodulation at measurements of 2 mg for every day.

anesthetic[1] [2] that has been sold online as a planner drug.[3] [4] [5] [6] It has additionally been proposed for the treatment of bacterial, contagious, viral or protozoal diseases and for immunomodulation at measurements of 2 mg for each day.[7]

Legitimate Status

Deschloroketamine is unlawful in Latvia,[8] and is canvassed by cover bans in Canada and the UK.


Edward G. Robins; Yongjun Zhao; Imtiaz Khan; Anthony Wilson; Sajinder K. Luthra; Erik Årstad (Walk 2010). “Union and in vitro assessment of 18 F-named S-fluoroalkyl diarylguanidines: Novel high-partiality NMDA receptor adversaries for imaging with PET”. Bioorganic and Therapeutic Science Letters. 20 (5): 1749–1751. PMID 20138515. doi:10.1016/j.bmcl.2010.01.052.

Calvin L Stevens (31 May 1966). “Patent US 3254124 – Aminoketones and strategies for their creation”. Recovered 2 October 2015.

Giampietro Frison; Luca Zamengo; Flavio Zancanaro; Francesco Tisato; Pietro Traldi (January 2016). “Portrayal of the creator medicate deschloroketamine (2-methylamino-2-phenylcyclohexanone) by gas chromatography/mass spectrometry, fluid chromatography/high-determination mass spectrometry, multistage mass spectrometry, and atomic attractive reverberation”. Quick Correspondences in Mass Spectrometry. 30 (1): 151–160. PMID 26661982. doi:10.1002/rcm.7425.

“Alerta: descloroketamina vendida como ketamina en Barcelona” (in Spanish). Vitality Control. Recovered 2 October 2015.

Juanjo Villalba (27 Walk 2015). “Los efectos desconocidos de la sequía de ketamina” (in Spanish). Bad habit. Recovered 2 October 2015.

Jeremy Knibbs (22 October 2015). “Gathering drug testing demonstrates its value”. The Therapeutic Republic.

Detlef Preiss; Akos Tatar (23 May 1995). “Patent DE4409671 – Utilization of 2-methylamino-2-phenylcyclohexanone for the treatment of bacterial, contagious, viral or protozoal contaminations and for immunomodulation”. Recovered 2 October 2015.

Noteikumi standard Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem

About The Author